Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?
Department of Medicine, University of Otago, Christchurch, New Zealand. Richard.Gearry@cdhb.health.nz.
Richard B
RB
Gearry
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000008:administration & dosage* / Q000494:pharmacology*; D007262:Infusions, Intravenous; D008214:Lymphocytes / Q000276:immunology*; D058990:Molecular Targeted Therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; C543529:vedolizumab; D000069285:Infliximab